je.st
news
Tag: gene
Did one gene mutation launch the Black Death?
2015-06-30 22:31:22| Biotech - Topix.net
One small genetic change may have transformed Yersinia pestis -- the plague bacteria -- from a relatively mild germ into the deadly bug that killed millions in the Black Death and other historic epidemics, scientists report. According to the U.S. Centers for Disease Control and Prevention, humans can contract Y. pestis after being bitten by a flea carried by a rodent or by handling the rodent themselves.
Celladon Terminates Development of Gene Therapy Mydicar
2015-06-26 16:43:09| Trucking - Topix.net
Celladon Corporation , today confirmed its plans to suspend further research or development of its MYDICAR program and its other pre-clinical programs including the Stem Cell Factor gene therapy and SERCA2b small molecule programs. Earlier in the month the Company announced the engagement of Wedbush PacGrow Healthcare as its exclusive financial advisor and a strategic plan pursuant to which the Company immediately commenced a process to seek a merger or sale.
Tags: development
therapy
gene
terminates
Top Biotech Stock Illumina Hunts For Breakout Gene
2015-05-30 23:09:13| Biotech - Topix.net
As medical sector stocks like AbbVie, Valeant and Regeneron continue to show strength, biotech and genomics leader Illumina is nearing a potential buy point. top biotech stock Illumina, IBD Stock Analysis, best medical sector stocks, big pharma, AbbVie, Valeant, Regneron, IBD Big Cap 20, how to read stock charts, base on base could be getting ready to break out.
Bluebird Bio: Transforming The Gene Therapy Landscape In Rare Diseases
2015-05-30 04:35:43| Trucking - Topix.net
Initial SCD data is due in June and significant upside remains if LentiGlobin proves to make a difference in patient lives. The company is in an excellent fundamental position and is well positioned to progress towards late-stage and regulatory submissions.
Merck and NanoString Announce Clinical Research Collaboration to Develop an Immune-Related Gene Expression Assay for Use in the Development Program for KEYTRUDA (pembrolizumab)
2015-05-28 14:30:00| Merck.com - Product News
Dateline City: KENILWORTH, N.J. & SEATTLE Collaboration Builds on Mercks R&D and NanoStrings Biomarker Development Leadership Positions in Immuno-Oncology Early Data Evaluating Immune-Related Signatures with KEYTRUDA in Multiple Cancers to be Presented for the First Time at 2015 ASCO Annual Meeting KENILWORTH, N.J. & SEATTLE--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, and NanoString Technologies, Inc. (NASDAQ:NSTG) today announced a clinical research collaboration to develop an assay that will optimize immune-related gene expression signatures and evaluate the potential to predict benefit from Mercks anti-PD-1 therapy, KEYTRUDA (pembrolizumab), in multiple tumor types. Language: English Contact: Merck Media Relations:Pamela Eisele, 267-305-3558Claire Mulhearn, 908-236-1118orMerck Investor Relations:Justin Holko, 908-740-1879orNanoString Investor/Media Relations:Leigh Salvo, 415-513-1281 Ticker Slug: Ticker: MRK Exchange: NYSE Ticker: NSTG Exchange: NASDAQ read more
Tags: for
research
development
program
Sites : [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] next »